The panel recommended the drug's approval with a 20-2 vote in February, after Vivus proposed a risk management program to limit Qsymia's distribution and published additional results from one of its three clinical trials.
At issue is a dearth of electrical components and zealous inventory management policies, which industry insiders say will limit supplies of smartphones, MP3 players, game consoles and televisions this holiday season.